Mineralys Therapeutics (MLYS) Total Current Liabilities (2022 - 2026)
Quarterly results put Total Current Liabilities at $14.7 million for Q1 2026, up 9.95% from a year ago — trailing twelve months through Mar 2026 was $14.7 million (up 9.95% YoY), and the annual figure for FY2025 was $15.1 million, up 3.19%.
Mineralys Therapeutics has reported Total Current Liabilities over the past 5 years, most recently at $14.7 million for Q1 2026.
- Total Current Liabilities reached $14.7 million in Q1 2026 per MLYS's latest filing, down from $15.1 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $31.3 million in Q3 2024 and bottomed at $6.2 million in Q2 2023.
- Median Total Current Liabilities over the past 5 years was $14.7 million (2024), compared with a mean of $16.5 million.
- The largest annual shift saw Total Current Liabilities surged 357.5% in 2024 before it plummeted 30.3% in 2025.
- Over 5 years, Total Current Liabilities stood at $8.1 million in 2022, then rose by 29.94% to $10.5 million in 2023, then soared by 39.73% to $14.6 million in 2024, then grew by 3.19% to $15.1 million in 2025, then dropped by 2.61% to $14.7 million in 2026.
- Business Quant data shows Total Current Liabilities for MLYS at $14.7 million in Q1 2026, $15.1 million in Q4 2025, and $23.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 5.11 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Mineralys Therapeutics | 2.50 Bn | 2.50 Bn | - | 14.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.72 Mn |
| Dec 31, 2025 | 15.11 Mn |
| Sep 30, 2025 | 23.52 Mn |
| Jun 30, 2025 | 22.17 Mn |
| Mar 31, 2025 | 13.39 Mn |
| Dec 31, 2024 | 14.65 Mn |
| Sep 30, 2024 | 31.32 Mn |
| Jun 30, 2024 | 28.40 Mn |
| Mar 31, 2024 | 19.20 Mn |
| Dec 31, 2023 | 10.48 Mn |
| Sep 30, 2023 | 13.54 Mn |
| Jun 30, 2023 | 6.21 Mn |
| Mar 31, 2023 | 10.56 Mn |
| Dec 31, 2022 | 8.07 Mn |